Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 2
2020 1
2021 1
2022 1
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
EGFR inhibition in EGFR-mutant lung cancer cells perturbs innate immune signaling pathways in the tumor microenvironment.
Shiiya A, Noguchi T, Tomaru U, Ariga S, Takashima Y, Ohhara Y, Taguchi J, Takeuchi S, Shimizu Y, Kinoshita I, Koizumi T, Matsuno Y, Shinagawa N, Sakakibara-Konishi J, Dosaka-Akita H. Shiiya A, et al. Among authors: ariga s. Cancer Sci. 2023 Apr;114(4):1270-1283. doi: 10.1111/cas.15701. Epub 2022 Dec 26. Cancer Sci. 2023. PMID: 36529523 Free PMC article.
Phase II trial of combination treatment with S-1/cetuximab in patients with platinum-ineligible recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Taguchi J, Shimizu Y, Ariga S, Goda T, Ohhara Y, Honma R, Noguchi T, Takeuchi S, Kinoshita I, Amano T, Mizumachi T, Kano S, Takahara M, Abe T, Homma A, Dosaka-Akita H. Taguchi J, et al. Among authors: ariga s. Int J Clin Oncol. 2021 Jan;26(1):51-58. doi: 10.1007/s10147-020-01788-6. Epub 2020 Sep 29. Int J Clin Oncol. 2021. PMID: 32996023 Clinical Trial.
Early prediction of treatment outcome for lenvatinib using 18F-FDG PET/CT in patients with unresectable or advanced thyroid carcinoma refractory to radioiodine treatment: a prospective, multicentre, non-randomised study.
Takeuchi S, Hirata K, Magota K, Watanabe S, Moku R, Shiiya A, Taguchi J, Ariga S, Goda T, Ohhara Y, Noguchi T, Shimizu Y, Kinoshita I, Honma R, Tsuji Y, Homma A, Dosaka-Akita H. Takeuchi S, et al. Among authors: ariga s. EJNMMI Res. 2023 Jul 17;13(1):69. doi: 10.1186/s13550-023-01019-9. EJNMMI Res. 2023. PMID: 37460834 Free PMC article.
Early prediction of lenvatinib treatment efficacy by using 18F-FDG PET/CT in patients with unresectable or advanced thyroid carcinoma that is refractory to radioiodine treatment: a protocol for a non-randomized single-arm multicenter observational study.
Takeuchi S, Shiga T, Hirata K, Taguchi J, Magota K, Ariga S, Gouda T, Ohhara Y, Homma R, Shimizu Y, Kinoshita I, Tsuji Y, Homma A, Iijima H, Tamaki N, Dosaka-Akita H. Takeuchi S, et al. Among authors: ariga s. BMJ Open. 2018 Aug 30;8(8):e021001. doi: 10.1136/bmjopen-2017-021001. BMJ Open. 2018. PMID: 30166292 Free PMC article.